Volume 94 Issue 40 | p. 15 | Concentrates
Issue Date: October 10, 2016

Merrimack cuts jobs and its CEO

Department: Business
Keywords: employment, oncology, cutbacks, systems biology

Merrimack Pharmaceuticals is narrowing its focus to several systems-biology-derived oncology drug candidates and its approved pancreatic cancer drug Onivyde, a liposomal formulation of irinotecan. It intends to eliminate more than $200 million in expenses over the next two years. The company has initiated an immediate 22% reduction in its staff, which was 426 employees as of January. Merrimack’s CEO, Robert Mulroy, also has resigned.

 
Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment